Abstract
Chemotherapy for advanced gastric and gastroesophageal junction carcinomas remains suboptimal. Both irinotecan (Camptosar) and cisplatin (Platinol) are active against this group of malignancies. This article focuses on the results of an ongoing phase II trial with this combination in patients with advanced gastric or gastroesophageal junction carcinoma. Data from this trial suggest that the combination of irinotecan and cisplatin is active in untreated as well as previously treated patients with gastric or gastroesophageal junction carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 19-21 |
| Number of pages | 3 |
| Journal | ONCOLOGY |
| Volume | 14 |
| Issue number | 12 SUPPL. 14 |
| State | Published - 2000 |
ASJC Scopus subject areas
- Oncology
- Cancer Research